Search Results - "Park, Keunchil"

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma by Kim, Nayoung, Kim, Hong Kwan, Lee, Kyungjong, Hong, Yourae, Cho, Jong Ho, Choi, Jung Won, Lee, Jung-Il, Suh, Yeon-Lim, Ku, Bo Mi, Eum, Hye Hyeon, Choi, Soyean, Choi, Yoon-La, Joung, Je-Gun, Park, Woong-Yang, Jung, Hyun Ae, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju, Lee, Hae-Ock

“…Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we…”
Get full text

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load by Jung, Hyunchul, Kim, Hong Sook, Kim, Jeong Yeon, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Esteller, Manel, Lee, Se-Hoon, Choi, Jung Kyoon

“…Mitotic cell division increases tumour mutation burden and copy number load, predictive markers of the clinical benefit of immunotherapy. Cell division…”
Get full text

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours by Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.

“…Background In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of…”
Get full text

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer by Hellmann, Matthew D, Paz-Ares, Luis, Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, de la Mora Jimenez, Emmanuel, Sakai, Hiroshi, Albert, Istvan, Vergnenegre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie R, O’Byrne, Kenneth J, Geese, William J, Bhagavatheeswaran, Prabhu, Rabindran, Sridhar K, Kasinathan, Ravi S, Nathan, Faith E, Ramalingam, Suresh S

“…Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus…”
Get full text

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases by Yang, James Chih-Hsin, Schuler, Martin, Popat, Sanjay, Miura, Satoru, Heeke, Simon, Park, Keunchil, Märten, Angela, Kim, Edward S

“…Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR…”
Get more information

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial by Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

“…Summary Background Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The anti-programmed death…”
Get full text

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study by Park, Keunchil, Haura, Eric B, Leighl, Natasha B, Mitchell, Paul, Shu, Catherine A, Girard, Nicolas, Viteri, Santiago, Han, Ji-Youn, Kim, Sang-We, Lee, Chee Khoon, Sabari, Joshua K, Spira, Alexander I, Yang, Tsung-Ying, Kim, Dong-Wan, Lee, Ki Hyeong, Sanborn, Rachel E, Trigo, José, Goto, Koichi, Lee, Jong-Seok, Yang, James Chih-Hsin, Govindan, Ramaswamy, Bauml, Joshua M, Garrido, Pilar, Krebs, Matthew G, Reckamp, Karen L, Xie, John, Curtin, Joshua C, Haddish-Berhane, Nahor, Roshak, Amy, Millington, Dawn, Lorenzini, Patricia, Thayu, Meena, Knoblauch, Roland E, Cho, Byoung Chul

“…Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor ( ) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved…”
Get full text

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial by Rittmeyer, Achim, MD, Barlesi, Fabrice, PhD, Waterkamp, Daniel, MD, Park, Keunchil, MD, Ciardiello, Fortunato, MD, von Pawel, Joachim, MD, Gadgeel, Shirish M, MD, Hida, Toyoaki, PhD, Kowalski, Dariusz M, PhD, Dols, Manuel Cobo, MD, Cortinovis, Diego L, PhD, Leach, Joseph, MD, Polikoff, Jonathan, MD, Barrios, Carlos, MD, Kabbinavar, Fairooz, MD, Frontera, Osvaldo Arén, MD, De Marinis, Filippo, MD, Turna, Hande, MD, Lee, Jong-Seok, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, He, Pei, PhD, Chen, Daniel S, MD, Sandler, Alan, MD, Gandara, David R, Dr

“…Summary Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and…”
Get full text

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity by Kim, Kwoneel, Kim, Hong Sook, Kim, Jeong Yeon, Jung, Hyunchul, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Lee, Se-Hoon, Choi, Jung Kyoon

“…Neoantigen burden is regarded as a fundamental determinant of response to immunotherapy. However, its predictive value remains in question because some tumours…”
Get full text

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 by Owonikoko, Taofeek K, Park, Keunchil, Govindan, Ramaswamy, Ready, Neal, Reck, Martin, Peters, Solange, Dakhil, Shaker R, Navarro, Alejandro, Rodríguez-Cid, Jerónimo, Schenker, Michael, Lee, Jong-Seok, Gutierrez, Vanesa, Percent, Ivor, Morgensztern, Daniel, Barrios, Carlos H, Greillier, Laurent, Baka, Sofia, Patel, Miten, Lin, Wen Hong, Selvaggi, Giovanni, Baudelet, Christine, Baden, Jonathan, Pandya, Dimple, Doshi, Parul, Kim, Hye Ryun

“…In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability…”
Get full text

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer by Jung, Hyun Ae, Noh, Jae Myoung, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Pyo, Hongryull, Ahn, Yong Chan, Park, Keunchil

“…•Real world data showed 55.3 % of patients did not meet the criteria of the PACIFIC study.•The incidence of grade 3 radiation pneumonitis was 18.2 % in…”
Get full text

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial by Park, Keunchil, Prof, Tan, Eng-Huat, MD, O'Byrne, Ken, Prof, Zhang, Li, Prof, Boyer, Michael, Prof, Mok, Tony, Prof, Hirsh, Vera, Prof, Yang, James Chih-Hsin, Prof, Lee, Ki Hyeong, MD, Lu, Shun, Prof, Shi, Yuankai, MD, Kim, Sang-We, MD, Laskin, Janessa, MD, Kim, Dong-Wan, Prof, Arvis, Catherine Dubos, MD, Kölbeck, Karl, MD, Laurie, Scott A, MD, Tsai, Chun-Ming, Prof, Shahidi, Mehdi, MD, Kim, Miyoung, MD, Massey, Dan, PhD, Zazulina, Victoria, MD, Paz-Ares, Luis, MD

“…Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line…”
Get full text

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer by Park, Sehhoon, Ock, Chan-Young, Kim, Hyojin, Pereira, Sergio, Park, Seonwook, Ma, Minuk, Choi, Sangjoon, Kim, Seokhwi, Shin, Seunghwan, Aum, Brian Jaehong, Paeng, Kyunghyun, Yoo, Donggeun, Cha, Hongui, Park, Sunyoung, Suh, Koung Jin, Jung, Hyun Ae, Kim, Se Hyun, Kim, Yu Jung, Sun, Jong-Mu, Chung, Jin-Haeng, Ahn, Jin Seok, Ahn, Myung-Ju, Lee, Jong Seok, Park, Keunchil, Song, Sang Yong, Bang, Yung-Jue, Choi, Yoon-La, Mok, Tony S, Lee, Se-Hoon

“…Biomarkers on the basis of tumor-infiltrating lymphocytes (TIL) are potentially valuable in predicting the effectiveness of immune checkpoint inhibitors (ICI)…”
Get full text

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial by Garon, Edward B, Dr, Ciuleanu, Tudor-Eliade, Prof, Arrieta, Oscar, MD, Prabhash, Kumar, Prof, Syrigos, Konstantinos N, Prof, Goksel, Tuncay, Prof, Park, Keunchil, Prof, Gorbunova, Vera, MD, Kowalyszyn, Ruben Dario, MD, Pikiel, Joanna, MD, Czyzewicz, Grzegorz, MD, Orlov, Sergey V, Prof, Lewanski, Conrad R, MD, Thomas, Michael, Prof, Bidoli, Paolo, MD, Dakhil, Shaker, MD, Gans, Steven, MD, Kim, Joo-Hang, Prof, Grigorescu, Alexandru, Prof, Karaseva, Nina, MD, Reck, Martin, MD, Cappuzzo, Federico, MD, Alexandris, Ekaterine, MS, Sashegyi, Andreas, PhD, Yurasov, Sergey, MD, Pérol, Maurice, MD

“…Summary Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of…”
Get full text

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer by Ku, Bo Mi, Bae, Yeon Hee, Lee, Kyoung Young, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju

“…Summary Entrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements in NTRK , ROS1 and ALK . The combined results of two clinical…”
Get full text

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung by Han, Ji-Youn, Park, Keunchil, Kim, Sang-We, Lee, Dae Ho, Kim, Hyae Young, Kim, Heung Tae, Ahn, Myung Ju, Yun, Tak, Ahn, Jin Seok, Suh, Cheolwon, Lee, Jung-Shin, Yoon, Sung Jin, Han, Jong Hee, Lee, Jae Won, Jo, Sook Jung, Lee, Jin Soo

“…Gefitinib has shown high response rate and improved progression-free survival (PFS) in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of…”
Get full text

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC by Kim, Youjin, Lee, Boram, Shim, Joon Ho, Lee, Se-Hoon, Park, Woong-Yang, Choi, Yoon-La, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil

“…EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Because co-occurring genomic alterations might describe different…”
Get more information

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial by Thatcher, Nick, Prof, Hirsch, Fred R, Prof, Luft, Alexander V, MD, Szczesna, Aleksandra, MD, Ciuleanu, Tudor E, Prof, Dediu, Mircea, MD, Ramlau, Rodryg, Prof, Galiulin, Rinat K, MD, Bálint, Beatrix, MD, Losonczy, György, Prof, Kazarnowicz, Andrzej, MD, Park, Keunchil, MD, Schumann, Christian, Prof, Reck, Martin, MD, Depenbrock, Henrik, MD, Nanda, Shivani, MS, Kruljac-Letunic, Anamarija, PhD, Kurek, Raffael, MD, Paz-Ares, Luis, MD, Socinski, Mark A, Prof

“…Summary Background Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with…”
Get full text

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial by Miller, Vincent A, Prof, Hirsh, Vera, MD, Cadranel, Jacques, Prof, Chen, Yuh-Min, MD, Park, Keunchil, Prof, Kim, Sang-We, Prof, Zhou, Caicun, Prof, Su, Wu-Chou, Prof, Wang, Mengzhao, Prof, Sun, Yan, Prof, Heo, Dae Seog, Prof, Crino, Lucio, Prof, Tan, Eng-Huat, MD, Chao, Tsu-Yi, Prof, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, James Chih-Hsin, Prof

“…Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer…”
Get full text

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial by Subbiah, Vivek, Gainor, Justin F, Oxnard, Geoffrey R, Tan, Daniel S W, Owen, Dwight H, Cho, Byoung Chul, Loong, Herbert H, McCoach, Caroline E, Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y, Kherani, Jennifer F, Huang, Xin, Kang, Suhyun, Drilon, Alexander

“…We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for fusion-positive non-small…”
Get full text